Ann: Half Year Accounts, page-2

Looks like they are airing more difficulties in recruiting patients for the trial and running out or COVID excuses - the timeline for ph3 read out now moves well into 2025 if you read between the lines.

I wonder how the market will react to this - obviously not good news that ph3 keeps on pushing out and the more money it will cost even the company needs to fund the highly paid execs longer before any real revenue is received.